Acumen Pharmaceuticals Inc
For the period ended Mar 31, 2024. Filed May 14, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 14, 2024
ABOS$0.24+6.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Balance Sheets
(in thousands, except share and per share data)
| March 31, 2024 | December 31, 2023 | |
|---|---|---|
| (unaudited) | ||
| ASSETS | ||
| Current assets | ||
| Cash and cash equivalents | $46,930 | $66,886 |
| Marketable securities, short-term | 205,582 | 176,636 |
| Prepaid expenses and other current assets | 3,319 | 3,093 |
| Total current assets | 255,831 | 246,615 |
| Marketable securities, long-term | 44,108 | 62,553 |
| Right-of-use asset | 353 | 381 |
| Restricted cash | 234 | 233 |
| Property and equipment, net | 117 | 122 |
| Other assets | 324 | 221 |
| Total assets | $300,967 | $310,125 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| Current liabilities | ||
| Accounts payable | $3,079 | $1,379 |
| Accrued clinical trial expenses | 2,367 | 4,387 |
| Accrued expenses and other current liabilities | 2,905 | 6,339 |
| Finance lease liability, short-term | — | 756 |
| Operating lease liability, short-term | 121 | 110 |
| Total current liabilities | 8,472 | 12,971 |
| Operating lease liability, long-term | 252 | 284 |
| Debt, long-term | 30,209 | 29,897 |
| Total liabilities | 38,933 | 43,152 |
| Commitments and contingencies (Note 10) | ||
| Stockholders’ equity | ||
| Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of March 31, 2024 and December 31, 2023 | — | — |
| Common stock, $0.0001 par value; 300,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 60,079,778 and 57,910,461 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively | 6 | 6 |
| Additional paid-in capital | 499,843 | 489,453 |
| Accumulated deficit | (237,671) | (222,798) |
| Accumulated other comprehensive income (loss) | (144) | 312 |
| Total stockholders’ equity | 262,034 | 266,973 |
| Total liabilities and stockholders’ equity | $300,967 | $310,125 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.